Purpose: This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC).
D URING THE year 2003, an estimated 31,900 new patients
with renal cell carcinoma (RCC) will be identified, and 11,900 RCC deaths will occur in the United States. 1 One third of RCC patients have metastatic disease at the time of diagnosis. 2 The 5-year overall survival of all RCC patients is 40% to 45% and has not appreciably improved in 25 years. 3 The median survival of patients with metastatic RCC is 10 months, with less than 2% long-term survival. 4 Locally advanced RCC is associated with a poor prognosis. Recurrence rates range from 50% to 85% depending on the tumor (T) stage and nodal (N) status for locally advanced RCC, 5, 6 and approach 100% in distant metastatic (M) disease that has been surgically removed. To date, no effective adjuvant therapy has been developed for patients with resected high-risk locally advanced or metastatic RCC. This includes local radiation to the tumor bed, systemic cytotoxic chemotherapy, or systemic immunotherapy. [7] [8] [9] [10] [11] [12] High-dose bolus interleukin-2 (IL-2) remains the only United States Food and Drug Administration-approved systemic therapy for metastatic RCC. Approval was based largely on the small percentage of durable complete remissions induced with such treatment. [13] [14] [15] Because of its well-established and extensively reported toxicity profile, 16, 17 treatment with high-dose IL-2 is confined to patients who have excellent functional status and who are treated at a few institutions that have experience with this treatment.
The Cytokine Working Group has extensive experience with high-dose IL-2. [18] [19] [20] Given its proven efficacy in the setting of metastatic disease, we hypothesized that treatment with highdose IL-2 might effectively limit recurrences in minimal disease states of RCC after complete surgical resection of locally advanced or distant metastatic disease. We hypothesized that if one course of high-dose bolus IL-2 could decrease this predicted recurrence rate significantly, it would be a reasonable adjuvant approach in this high-risk population, despite its toxicity. We therefore performed a prospective, randomized phase III trial comparing one course of high-dose bolus IL-2 versus observa-tion (which is the standard of care for resected RCC) with the option of using an IL-2-based therapy at the time of recurrence.
PATIENTS AND METHODS

Patients
Patients were eligible for enrollment onto this trial if they were older than 16 years and had completely resected advanced high-risk RCC as defined by one of the following pathologic stages: T3b-c, T4, N1-3, or M1 disease resected to no evidence of disease (NED; Table 1) . 21 Patients must have recovered from any effects of surgery, which must have been performed within 12 weeks of enrollment. The patients had to meet the following eligibility criteria: an excellent performance status (Eastern Cooperative Oncology Group performance status of 0 or 1); adequate organ function defined as WBC count Ն 4,000/L, platelet count Ն 100,000/L, hemoglobin Ն 10 g/dL, serum creatinine Յ 1.5 mg/dL or creatinine clearance Ն 60 mL/min, and direct bilirubin Յ 1.5 mg/dL; and forced expiratory volume at 1 second more than 2.0 L or 75% of predicted for height and age from pre-enrollment pulmonary function testing. No history or evidence of cardiac disease on ECG was allowed, and a normal cardiac stress test was required for all patients older than 40 years of age. No prior systemic treatment for RCC was allowed, but patients may have received prior locoregional radiation therapy to solitary resectable metastases, which must have undergone surgical resection before enrollment. No prior history of invasive malignancy in the past 5 years or human immunodeficiency virus positivity was allowed; female patients were required to have a negative pregnancy test; and all patients were required to give written informed consent to participate. The institutional review boards for the protection of human subjects at each participating institution approved the study.
Randomization, Treatment, and Follow-Up
At the time of enrollment, patients were assigned to one of four stratification groups on the basis of the pathologic stage of their disease: T3b or N1 disease, T3c-4 disease, N2-3 disease, or M1 disease resected to NED. Histologic categorization of the primary RCC was not used prospectively as a stratification criterion. Patients were then randomly assigned in a 1:1 fashion to treatment with one course of high-dose bolus IL-2 or observation. Disease characteristics between the two treatment groups were compared at randomization using the 2 test and the Student's t test for categorical and continuous variables, respectively.
The IL-2 (Proleukin; Chiron Corp, Emeryville, CA) was administered in standard fashion: 600,000 U/kg as an intravenous bolus over 15 minutes every 8 hours on days 1 to 5, and again on days 15 to 19, for a maximum of 28 doses as an inpatient, often on a unit with intensive care-level monitoring capabilities. Standard supportive therapy was used to treat the typical IL-2-induced capillary leak syndrome, including low-dose vasopressor support, antipyretics, antinausea, and antidiarrheal medications. 20 Follow-up was identical for the two study arms: patients underwent evaluation with office visits, laboratory work-ups, and radiographic imaging (computed tomography scan and bone scan) every 3 months for 2 years, then every 4 months for 1 year, then every 6 months during years 4 and 5, then yearly until recurrence or death. Documentation of recurrence was based on radiographic and clinical findings.
Objectives and Statistical Analysis
The primary objective of this randomized phase III trial was to evaluate the effect of one course of adjuvant high-dose IL-2 on disease-free survival (DFS) after complete resection of high-risk locally advanced RCC, compared with observation alone. DFS was calculated from the date of random assignment to treatment to documented recurrence or death; patients remaining disease-free were censored at the date of last follow-up. Secondary objectives were to compare overall survival in the treatment and control arms of this study, and to assess the overall tolerability, toxicity, and safety of high-dose bolus IL-2 as adjuvant treatment in patients with resected high-risk RCC. Survival and DFS were estimated on the basis of Kaplan-Meier methods 22 ; differences between treatment groups were compared with the log-rank test. On the basis of available data, the 2-year DFS in the control group of patients with resected locally advanced RCC was estimated to be 40%. 5, 6 This study was powered to show an absolute increase in DFS from 40% to 70% in the observation group compared with the treatment group, or a relative increase in DFS of 75%. Sixty-eight patients with locally advanced RCC (34 per group) would be required to achieve a power of 80% to detect this significant difference in DFS with a two-sided alpha level of .05. The major analysis was to be based on the intention-to-treat principle. The projection of 68 patients was exclusive of the patients with M1 disease resected to NED because this population was expected to be a small component of the total number enrolled and these patients might exhibit an unpredictable natural history. Although specific treatment after recurrence was left to the discretion of the treating physician, it was expected that the majority of patients who experienced relapse in the control group would be treated with IL-2-based therapy. A secondary analysis, therefore, was 
Primary tumor (T)
TX Primary tumor cannot be assessed T0 No evidence of primary tumor T1 Tumor 7.0 cm or less in greatest dimension limited to the kidney T2 Tumor more than 7.0 cm in greatest dimension limited to the kidney T3 Tumor extends into major veins or invades the adrenal gland or perinephric tissues but not beyond Gerota's fascia T3a Tumor invades the adrenal gland or perinephric tissues but not beyond Gerota's fascia T3b Tumor grossly extends into the renal vein(s) or vena cava below the diaphragm T3c Tumor grossly extends into the vena cava above the diaphragm T4 Tumor invades beyond Gerota's fascia Regional lymph nodes (N)* (includes: renal hilar; paracaval; aortic [para-aortic, periaortic, lateral aortic]; retroperitoneal) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in a single lymph node, 2 cm or less in greatest dimension N2 Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension N3 Metastasis in a lymph node more than 5 cm in greatest dimension Distant metastasis ( planned to compare outcomes of adjuvant IL-2 with those of IL-2 after tumor recurrence following surgery in this patient sample.
Interim Data and Safety Monitoring
Interim monitoring guidelines were adopted to address early stoppage of the study for treatment differences, negative results, and safety concerns related to serious adverse reactions to high-dose IL-2. Safety monitoring was conducted by a formal external data and safety monitoring committee (DSMC). Significance levels for early stoppage were to be based on the techniques of Fleming et al. 23 Formal interim analyses were to be conducted after 40 patients with locally advanced disease had been accrued (for efficacy analysis), and at the completion of years 2 and 3 of the study (for safety analysis), with an unexpected adverse reaction rate of greater than 15% justifying early stoppage of the study. A component of this analysis was a conditional probability estimate to address the likelihood that no treatment difference would be detected at the conclusion of the study. The final analysis was to occur at the conclusion of the study; the required P value to achieve statistical significance at that time was .04.
RESULTS
Between September 1997 and June 2002, 69 patients at 15 institutions were accrued to this trial. Enrollment was expected to occur over a 3-year period; however, initial accrual of the primary subjects of interest (ie, those with T3c-4 primary tumors or N2-3 nodal involvement) was much slower than anticipated. To increase accrual, in June 1998, the study was amended to include patients with slightly lower risk disease (T3b or N1). Accrual of the target population was subsequently anticipated to require 5 years from trial initiation.
Patients were stratified according to stage, and the various subsets of disease were evenly distributed between treatment arms (Table 2) . Twenty-one patients in the IL-2 arm and 23 patients in the observation arm had locally advanced high-risk disease; the remainder had M1 disease resected to NED. More patients with RCC not otherwise specified were randomly assigned to receive IL-2, whereas the control arm contained a greater proportion of patients with clear-cell histology; these differences were not statistically significant.
The toxicity of the high-dose IL-2 was as expected. There were no unexpected adverse events or treatment-related deaths as a result of this therapy (Table 3) . Eighty-eight percent of the 33 patients treated with IL-2 experienced at least one grade 3 or 4 toxicity. The most common grade 3 or 4 toxicity was hypotension, which required vasopressor support and occurred in 52% of patients. Serious cardiac or CNS toxicities were rare. All toxicities resolved after discontinuation of therapy. The median number of doses received in the treatment arm was 20 of a maximum of 28 (range, 6 to 28 doses), which is consistent with dosing experienced in advanced disease trials. 24 The range and median number of doses were similar for patients with locally advanced disease and those with resected metastases.
After 38 patients with locally advanced high-risk disease (T3b-4 or N1-3) were enrolled and had undergone adequate follow-up, an interim analysis of DFS was performed by the DSMC, as called for in the protocol. At the time of the analysis, 23 of these patients had disease progression or death. The expected total number of events at 2 years of follow-up was 32 in the target population of 68 patients with locally advanced disease, or 34 patients in each arm (21 events in the observation arm and 11 events in the treatment arm, respectively). Thus, 72% of the expected events had occurred at the time of the interim analysis. The conditional probability calculation for comparison of DFS revealed a less than 1% chance of observing the minimum 30% actual improvement in 2-year DFS, which was prospectively defined, if the trend of events continued with full accrual. It was therefore concluded by the DSMC that there was no evidence to indicate that IL-2 would have the projected 30% absolute increase in 2-year DFS over that of observation (Table  4 ). The same conclusion was reached whether the entire patient population (Fig 1) or only patients with locally advanced high-risk disease were analyzed (Fig 2) . Figure 3 indicates the DFS for those patients having undergone metastasectomy before enrollment. The median DFS for all patients enrolled was 28 months. The investigators unanimously concluded, therefore, that given the minimal likelihood that one course of IL-2 adjuvant therapy would demonstrate the clinically significant benefit projected, continued accrual to the trial was not justified. The totals outlined in all Tables and Figures indicate all patients enrolled and thus are different from those used in the interim analysis because not all patients accrued had undergone adequate follow-up at the time of the DSMC analysis.
Overall survival was similar between treatment arms and stratification groups (Table 4 and Fig 4, 5, and 6) , with a median follow-up for all enrolled patients of 22 months. Sites of recurrence were similar in each group; the lung was the most common site of recurrence (observed in 30% of patients with recurrent disease). Of the 20 patients randomly assigned to observation who developed recurrence, five patients went on to receive standard high-dose bolus IL-2 systemic therapy. Most patients were enrolled onto another clinical trial during which they received another form of an IL-2-based systemic immunotherapy regimen. One patient underwent surgical resection of his recurrent disease; four other patients were still contemplating treatment options at last follow-up.
DISCUSSION
In this trial, we set out to evaluate the potential role of high-dose bolus IL-2 as systemic adjuvant therapy for patients with resected high-risk RCC. We assessed the efficacy and tolerability of this approach in a patient population with known poor long-term outcome. Although the trial was terminated early according to recommendations of an official DSMC after an interim analysis performed at a predetermined evaluation time point, it was clear that even if full accrual to the trial had occurred, the projected improvement in DFS would not be observed. Overall survival was not affected by this treatment. Toxicity, although significant, was typical for one course of Abbreviations: IL-2, interleukin-2; OBS, observation; NA, not available; CI, confidence interval. systemic high-dose bolus IL-2 and was completely reversible. The number of doses of IL-2 administered to patients was consistent with prior published series for patients with unresected advanced RCC. 24 The study did confirm that the patients selected for this trial were at high risk for recurrence.
Many other treatments have been evaluated in the adjuvant setting for RCC. [6] [7] [8] [9] [10] [11] [12] Thus far, none have resulted in an improvement in outcome. The largest trial to date tested lymphoblastoid interferon as adjuvant postoperative treatment in patients with resected stage III RCC. 6, 11 Although no benefit was observed in progressionfree or overall survival, the study did identify a subgroup of patients who were at high-risk for recurrence. 5, 6 Among the 294 patients enrolled, those with T3c or N2 disease had only a 25% and 18% 2-year DFS, respectively. We initially chose to target this subgroup of high-risk patients in our study to minimize exposure of a lower risk population to the substantial toxicity of high-dose IL-2. As outlined above, however, because of poor accrual we expanded the eligibility criteria 1 year later to include somewhat lower risk patients with T3b or N1 disease. In the prior study, the 2-year DFS for these populations was 50% and 43%, respectively. In another large randomized study, a similarly lower risk group of 247 patients with resected stage II and III RCC were assigned to treatment with interferon alfa-2b or observation. 12 Again, no benefit from postoperative adjuvant immunotherapy was observed.
One potential limitation to our study may have been the restriction of postoperative therapy to one course of high-dose bolus IL-2. High-dose bolus IL-2 remains the only United States Food and Drug Administration-approved treatment for advanced or metastatic RCC. Because of the documented durable complete responses observed with this dose and schedule of IL-2 in patients with metastatic disease, [13] [14] [15] we believed that testing high-dose bolus IL-2 as adjuvant therapy was justified in the identified high-risk population, despite its toxicity. The choice of only one course of therapy as adjuvant treatment was based on the following rationales. First, the vast majority of responders with advanced RCC do so after one course of therapy; no definitive evidence exists that more than one course of this treatment offers a significant benefit in the setting of metastatic or unresectable disease because most patients still show interval shrinkage at the time of the second course of therapy. It has been well documented that the total IL-2 administered to patients on a second course is substantially less than that administered in the first course.
13,14 Second, the patients to be treated on this study would have had resection of all clinically detectable disease; it would therefore be impossible to document whether individual patients had benefited at all, let alone sufficiently to justify the expense and risk of a second course of therapy. Given this minimal residual disease state and our unwillingness to subject patients to excessive risk, we presumed that one course of IL-2 would be adequate.
Another potential limitation might be the highly selected patient population on which we focused. Limiting initial accrual to patients with resected T3c or N2 or greater disease led to slow enrollment. It became clear to us that patients with such locally advanced disease do not commonly undergo surgical resection for curative intent or are rarely referred for potential adjuvant therapy. Expansion of enrollment to include a lower risk group allowed for enhanced accrual; nevertheless, the other obstacles to accrual, such as physician or patient bias about randomized trials and the fact that high-dose IL-2 is only administered in specialized centers, led to continued slow accrual.
The potential impact of unbalanced randomization with regard to tumor histologic subtype may have been a contributing factor to the negative outcome of this study, although this is unlikely. Histologic subtype was not prospectively defined as a stratification factor; thus, Table 2 shows that more patients with RCC not otherwise specified were randomly assigned to receive IL-2, whereas more patients with clear-cell type were randomly assigned to observation. The 2 test reveals that these differences between treatment groups were not statistically significant, however (P ϭ .12). It is possible that this difference may have been important, albeit not statistically significant. That is, the natural history of untreated variant histology RCC versus that of clear-cell RCC is not known. It has been shown however, that advanced-disease patients with clear-cell histology RCC attain a greater benefit from IL-2 therapy; 25 this information was not known to us until after the trial was closed. If the patients with RCC not otherwise specified exhibited variant histology more commonly than clear-cell histology, fewer patients than anticipated might have been able to benefit from IL-2 treatment because more patients with clear-cell type were randomly assigned to the observation arm. The limitations of our database do not allow us to look back at these specific histologic subtypes; however, future adjuvant trials should include better pathologic stratification and pathologic review at enrollment.
It is likely that an absolute improvement in DFS as large as 30% (75% relative improvement) was far too ambitious, considering that high-dose bolus IL-2 is associated with an objective overall response rate of only 15% to 20% in high-performance patients with advanced RCC. However, we believed that only a large improvement in DFS could justify the potential risk and expense of IL-2 therapy in this patient population.
Our study failed to show the anticipated significant clinical advantage to postoperative systemic IL-2 in patients with resected RCC at high-risk for recurrence. On the basis of our results, however, a benefit of less magnitude that might still be of clinical benefit cannot be ruled out. The question arises as to whether it was appropriate to study the efficacy of high-dose bolus IL-2 in patients with resected regional nodal metastases. In one retrospective review, patients presenting with distant metastatic disease along with regional lymphadenopathy experienced a decreased survival compared with those patients without nodal involvement. 26 These patients with locally advanced and distant disease did not appear to benefit from IL-2-based immunotherapy after cytoreductive surgery. 26 Another question is whether high-dose IL-2 is the proper agent to study. As noted, overall response rates in advanced RCC are 15% to 20%. The likelihood, therefore, of observing a meaningful advantage using this agent in the adjuvant setting might have been predicted to be low. Evaluation of adjuvant therapy using a more effective systemic immunotherapy in advanced disease RCC patients makes more sense. Unfortunately, to date, no such therapy exists. Active immunotherapeutic regimens reported for advanced RCC generally have no greater overall response rates or durable remissions than those reported for high-dose IL-2.
27-30 A more relevant question then becomes whether adjuvant trials in RCC should even be considered until more effective agents or at least an effective immune regimen that induces an immune response in a majority of patients becomes available. Until such a time, the standard of care for fully resected RCC remains observation.
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